Yoshimi Endo Greer, M.D., Ph.D.
Dr. Yoshimi Greer has extensive experience in cell biology and biochemistry in the signal transduction field. She identified a number of molecular mechanisms that explain how the Wnt signaling pathway controls morphological changes in mammalian cells, including cancer cells. She has also been studying the mechanism of DNA damage caused by lack of casein kinase 1 delta. Recently, Dr. Greer extended her interest to breast cancer research and joined Dr. Stan Lipkowitz’s lab where she has been investigating the mechanism of TRAIL-induced cell death in breast cancer cells, and seeking its potential clinical application in cancer treatment.
Dr. Greer's long-term focus has been the Wnt signaling pathway, which is highly involved in a variety of human cancers as well as in embryonic development. Through an active collaboration, Dr. Greer investigated the functional consequences of Wnt-induced Dishevelled2 phosphorylation in canonical and non-canonical Wnt signaling. Furthermore, she identified atypical protein kinase C iota as a factor that is required for Wnt3a-dependent neurite outgrowth and binds to phosphorylated Dishevelled2. Dr. Greer's most recent discovery showed that the casein kinase 1 delta (CK1delta) located at the centrosome is required for Wnt-3a-dependent neurite outgrowth. Currently, Dr. Greer has been exploring further functional roles of CK1delta in other model systems.
Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1..[ Journal Article ]
- Mol Biol Cell. 25: 1629-40, 2014. [ Journal Article ]
Atypical protein kinase Cι is required for Wnt3a-dependent neurite outgrowth and binds to phosphorylated dishevelled2.J Biol Chem. 288: 9438-46, 2013. [ Journal Article ]
Functional consequences of Wnt-induced dishevelled2 phosphorylation in canonical and non-canonical Wnt signaling.J Biol Chem. 288: 9428-37, 2013. [ Journal Article ]
Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility.Oncogene. 32: 3246-53, 2012. [ Journal Article ]
Dr. Yoshimi Greer obtained her M.D. in 1994 from Tohoku University School of Medicine in Sendai, Japan. After graduation, she conducted her clinical residency training in internal medicine at Tohoku University Hospital for 5 years. Dr. Greer obtained a Ph.D. in renal physiology in 1999 at the Graduate School of Tohoku University; her dissertation research focused on the role of the Ang II receptor blocker on micro-hemodynamics in animal kidney model systems. Dr. Greer joined Dr. Josephine P. Briggs' lab at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a postdoctoral fellow in 1998 where she studied the transcriptional regulatory mechanism of COX-2.
In 2001, Dr. Greer joined Dr. Jeff Rubin's lab at the NCI-CCR. While in Dr. Rubin’s lab, she studied the molecular mechanism of Wnt3a-dependent cell motility in mammalian cells. In 2004, Dr. Greer joined Georgetown University Medical School as a research instructor (junior faculty) and studied the transcriptional mechanism of VE-cadherin that is involved with retinoic acid-mediated trans-differentiation of breast cancer cells. In 2006, Dr. Greer returned to NCI as a research fellow and continued her Wnt signal research. She discovered the molecular mechanisms that explain how Wnt-3a stimulates neurite outgrowth in Ewing tumor cells. In 2009, she became a staff scientist in the Laboratory of Cellular and Molecular Biology, CCR . She identified casein kinase 1 delta, a kinase involved in Wnt signaling, that plays an essential role in neurite outgrowth, ciliogenesis and DNA damage control. In October 2014, she joined Dr. Stan Lipkowitz’s lab because she has a great interest in translational research. Dr. Greer is now studying TRAIL-induced cell death mechanism in breast cancer cells.